Rx to OTC Switch Forecasts

Rx-to-OTC Switch Forecasts USA: Next Frontier 

Published August 2017
Base Year: 2017
Forecasts to 2022
Regional Coverage: United States

This report provides subscribers with a comprehensive, objective assessment of the Rx-to-OTC switch landscape including forecasts of future switches in the United States. This report provides forecasts of switches in existing OTC categories and projections for new OTC categories. The study provides a broad assessment of “switchable” OTC categories, a specific analysis and forecasts of most likely switch categories and drugs, and an analysis of regulatory and retail paradigm shifts and implications for future switches.

This Report Helps Subscribers to:

  • Assess Rx-to-OTC switch forecasts by category
  • Analyze regulatory and retail paradigm shifts and implications for future switches
  • Cast a wide-net analysis for uncovering potential licensing opportunities
  • Specific analysis and forecasts of the most likely switch drugs/categories

Report Contents

Introduction

Executive Summary
Overview of key findings and trends

  • Regulatory considerations for switches
  • Recent switches
  • Switch forecasts
  • Competitive landscape
  • Conclusion and appraisal

Switch Forecasts by Category
For each of the categories shown in Table 1, the following information is provided:

  • Comparative analysis of Rx and OTC markets (where applicable)
  • Regulatory considerations
  • Safety/efficacy
  • Patent status
  • Potential nonprescription drugs claims
  • Likelihood of switch and expected timing
  • OTC sales forecasts
  • Expected competitive response from both branded and private-label products

FutureView Forecasting Model
This report includes access to Kline’s proprietary and interactive FutureView forecasting model, which is an Excel-based model accessed online. The model provides Kline’s assumptions about the probability of switch and sales forecasts by brand and therapeutic class. The assumptions in the model can be changed by users to revise sales forecasts or probabilities for classes/drugs included in this analysis or for other classes/drugs not profiled.

Table 1: List of Categories Analyzed
Acne
Allergy
Benign prostatic hyperplasia
Digestive products
Erectile dysfunction
Migraine
Overactive bladder
Sleeping aids
Skin rash/eczema psoriasis
Topical pain relievers

Kline’s FutureView Forecasting Model

Scope & Benefits

Rx-to-OTC Switch Forecasts USA: Next Frontier represents the 12th edition in Kline’s venerable series of reports on Rx-to-OTC switches. With this study, we uncover opportunities for future switches in the U.S. market. This study will attempt to understand how shifts in regulations, retail environment, and technology may have significant impacts on future switches. This report covers the U.S. market for Rx-to-OTC switches and provide sales forecasts through 2022. Full subscribers to this report are entitled to access to Kline’s proprietary FutureView Forecasting Model, which helps predict the likelihood of switches, as well as sales forecasts for switch brands and categories.t

For consumer health marketers, Rx-to-OTC Switch Forecasts USA: Next Frontier examines the key issues and implications that switches can have on existing OTC businesses and identify opportunities for future growth from switches. Accurately predicting Rx-to-OTC switches and assessing their impact is crucial for maximizing business opportunities, minimizing threats, and successfully constructing long-term strategic plans. Specifically, the report provides subscribers with the following key deliverables:

  • Up-to-date primary research on switches conducted with knowledgeable industry participants
  • Casts a wide-net analysis to uncover potential licensing opportunities
  • Realistic assessment of regulatory climate and future implications
  • An understanding of implications of future switches on existing OTC categories
  • Identification of future opportunities by identifying categories with high likelihood of switch, and forecasting sales potential and likely timing

Price Anchor

Request Information

OTHER RX-TO-OTC SWITCH REPORTS

Posted in .